4D Molecular Therapeutics reported Q2 2025 financial results, with $417 million in cash as of June 30, 2025, expected to fund operations into 2028. The 4D-150 Phase 3 program in wet AMD is progressing ahead of schedule, with 4FRONT-1 data readout now expected in H1 2027 and 4FRONT-2 initiated early. Positive 60-week results from the 4D-150 SPECTRA trial in DME were also presented.

The company streamlined its organization to focus on late-stage execution and drive Phase 3 development of 4D-150. A workforce reduction of 25% was announced, providing $15 million in annual cash compensation cost savings. 4D-150 for Wet AMD saw strong progress, with accelerated timelines and positive 60-week results from the SPECTRA clinical trial in DME.

In pulmonology, the 4D-710 program for Cystic Fibrosis Lung Disease completed enrollment of Cohort 4 in the Phase 1 stage of the AEROW clinical trial. Interim data and program updates are expected in Q4 2025. Overall, 4D Molecular Therapeutics is focused on advancing disease-targeted therapeutics with potential to transform treatment paradigms.

Read more at GlobeNewswire: 4DMT Reports Second Quarter 2025 Financial Results,